Here's the Data Supporting Pegcetacoplan's Approval in Two Rare Kidney Diseases

(MedPage Today) — Pegcetacoplan (Empaveli) reduced proteinuria and helped stabilize kidney function in patients with C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis (MPGN), the phase III VALIANT trial found…

Source link : https://www.medpagetoday.com/nephrology/generalnephrology/118824

Author :

Publish date : 2025-12-03 23:16:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

Here’s the Data Supporting Pegcetacoplan’s Approval in Two Rare Kidney Diseases

A Dozen Former FDA Leaders Lambast Claims by Current FDA Vaccine Chief

Related Posts

A Dozen Former FDA Leaders Lambast Claims by Current FDA Vaccine Chief

Senators Wrestle With ACA Subsidy Issue During Hearing

Doctor Who Sold Ketamine to ‘Friends’ Star Matthew Perry Gets 2.5 Years in Prison

Spatial Omics May Transform the Future of Breast Cancer Treatment

Belly Fat May Be Stronger Predictor of Heart Damage Than BMI

One Dose of HPV Vaccine Just as Effective as Two, Trial Finds

Here’s the Data Supporting Pegcetacoplan’s Approval in Two Rare Kidney Diseases

A Dozen Former FDA Leaders Lambast Claims by Current FDA Vaccine Chief

Senators Wrestle With ACA Subsidy Issue During Hearing

Doctor Who Sold Ketamine to ‘Friends’ Star Matthew Perry Gets 2.5 Years in Prison

Spatial Omics May Transform the Future of Breast Cancer Treatment

Belly Fat May Be Stronger Predictor of Heart Damage Than BMI

One Dose of HPV Vaccine Just as Effective as Two, Trial Finds

FDA Approves Another Neulasta Biosimilar

Categories

Archives